The European Pharmaceutical Safety Committee concluded that the use of the famous weight loss drug in Novo Nordsek He wrapped up and Treats of diabetes type 2 It may cause rare incidents from a possible eye condition.
The organizer said on Friday that the condition called NGOs (NAION) may affect up to 1 out of every 10,000 people who take the toxelotide, which is the active component of Wegovy and Novo Diabetes OzemPic and Rybelsus.
EMA, which started to review in December, said that the use of drugs is linked to an increase in two parts at the risk of developing the condition compared to people who do not take the drug.
NAION develops from insufficient blood flow to the optic nerve and causes painless vision loss in one eye. This is the second most common cause of blindness due to optic nerve damage, after glaucoma.
Semaglutide studies have been linked to NAION in the past. But this is the first time that the link has been made.
Get weekly health news
Receive the latest medical news and health information provided to you every Sunday.
Semaglutide belongs to a group of drugs known as the GLP-1 receptors, which works by helping to control blood sugar levels and create a feeling of fullness.
A large study that witnessed nearly 350,000 diabetes published earlier this year showed that the risk of developing NAION is more than twice after use in the long term of siaglotide, compared to patients who take medicines from other groups.
EMA said it has reviewed all available data on NAION with Semaglutide, including data from non -clinical studies, clinical experiences and surveillance after marketing.
The pharmaceutical maker has recommended updating the descriptive information of drugs containing Smaglutide to include NAION as side effects with a “very rare” frequency.
The US Food and Drug Administration did not immediately respond to Reuters request for comment.
https://globalnews.ca/wp-content/uploads/2024/09/ozempic-2.jpg?quality=85&strip=all&w=720&h=379&crop=1
Source link